A Novel Investigational Fc-Modified Humanized Monoclonal Antibody, Motavizumab-YTE, Has an Extended Half-Life in Healthy Adults

Robbie, Gabriel J., Criste, Ryan, Dall'Acqua, William F., Jensen, Kathryn, Patel, Nita K., Losonsky, Genevieve A., Griffin, M. Pamela·2013·Antimicrobial Agents and Chemotherapy
DOI 10.1128/aac.01285-13

Cited by (366)

Items 201–300 of 366

  1. Biology and Behavior of Severe Acute Respiratory Syndrome Coronavirus Contagion with Emphasis on Treatment Strategies, Risk Assessment, and Resilience
    James Baldwin, Samina Noorali, Ashok Vaseashta · 2023 · COVID
  2. Insight into the avidity–affinity relationship of the bivalent, pH-dependent interaction between IgG and FcRn
    Johannes Reusch, Jan Terje Andersen, Ulrich Rant, Tilman Schlothauer · 2024 · mAbs
  3. Preclinical and Clinical Investigations of Potential Drugs and Vaccines for COVID-19 Therapy: A Comprehensive Review With Recent Update
    Md. Easin Mia, Mithu Howlader, Farzana Akter, Md. Murad Hossain · 2024 · Clinical Pathology
  4. Current status and prospect for future advancements of long-acting antibody formulations
    Puneet Tyagi, Garrett Harper, Patrick McGeehan, Shawn P. Davis · 2023 · Expert Opinion on Drug Delivery
  5. IMGT® Nomenclature of Engineered IGHG Variants Involved in Antibody Effector Properties and Formats
    Marie‐Paule Lefranc, Gérard Lefranc · 2022 · Antibodies
  6. Generation and preclinical assessment of depemokimab, an enhanced IL-5 antagonist monoclonal antibody
    Martin Orecchia, Katherine Welbeck, Jason Dexter, Laura Hook, Chika Akinseye, Marcin Kot, Alan Lewis, Don O. Somers, Tejinder Bhinder, Paul Hamblin et al. · 2025 · Heliyon
  7. Mechanism-Based Competitive Binding Model to Investigate the Effect of Neonatal Fc Receptor Binding Affinity on the Pharmacokinetic of Humanized Anti-VEGF Monoclonal IgG1 Antibody in Cynomolgus Monkey
    Chee M. Ng, Paul J. Fielder, Jin Jin, Rong Deng · 2016 · The AAPS Journal
  8. Animal Models, Therapeutics, and Vaccine Approaches to Emerging and Re-Emerging Flaviviruses
    Thomas J. Baric, Z. Beau Reneer · 2024 · Viruses
  9. Prediction of human pharmacokinetics of Fc-engineered therapeutic monoclonal antibodies using human FcRn transgenic mice
    Kenta Haraya, Takuya Ichikawa, Naoaki Murao, Hitoshi Katada, Taichi Kuramochi · 2025 · mAbs
  10. Mechanistic incorporation of FcRn binding in plasma and endosomes in a whole body PBPK model for large molecules
    Wilhelmus E. A. de Witte, Lindsay B. Avery, Brian C. Mackness, Tom Van Bogaert, Anna Park, Maria Laura Sargentini‐Maier · 2023 · Journal of Pharmacokinetics and Pharmacodynamics
  11. Respiratory Syncytial Virus Vaccines
    Ruth A. Karron · 2017 · Elsevier eBooks
  12. Biobetter Biologics
    Alexandra Beumer Sassi, Radhika P. Nagarkar, Paul Hamblin · 2015 · Elsevier eBooks
  13. Antibody Therapy: From Diphtheria to Cancer, COVID-19, and Beyond
    Deepak Kumar, Sulgey Gauthami, Jagadeesh Bayry, Srini V. Kaveri, Nagendra R. Hegde · 2021 · Monoclonal Antibodies in Immunodiagnosis and Immunotherapy
  14. Chimerism of avian IgY‐scFv and truncated IgG‐Fc : A novel strategy in cross‐species antibody generation and enhancement
    Shikun Ge, Alberto Carlos Pires Dias, Xiaoying Zhang · 2024 · Immunology
  15. Current and future use of antibody-based passive immunity to prevent or control HBV/HDV infections
    Adam J. Gehring, Loghman Salimzadeh · 2024 · Antiviral Research
  16. Comprehensive approaches to preclinical evaluation of monoclonal antibodies and their next-generation derivatives
    Santanu Singh, Kajal Kachhawaha, Sumit K. Singh · 2024 · Biochemical Pharmacology
  17. Modulation of the pharmacokinetics of soluble ACE2 decoy receptors through glycosylation
    Savanna S. Skeeters, Kamal Bagale, Galina A. Stepanyuk, David F. Thieker, Aaron Aguhob, Kui K. Chan, Benjamin Dutzar, Sergei S. Shalygin, Asif Shajahan, Yang Xu et al. · 2024 · Molecular Therapy — Methods & Clinical Development
  18. Half-life extension of therapeutics: Applications and mechanisms
    Kishore Pathivada, Patrick M. Glassman · 2025 · Journal of Pharmacology and Experimental Therapeutics
  19. Clinical Immunogenicity Risk Assessment Strategy for a Low Risk Monoclonal Antibody
    Robert M. Kernstock, Gizette V. Sperinde, Deborah Finco, Roslyn Davis, Diana L. Montgomery · 2020 · The AAPS Journal
  20. Predicting Method for the Human Plasma Concentration–Time Profile of a Monoclonal Antibody from the Half-life of Non-human Primates
    Genki Nakamura, Kazuhisa Ozeki, Miho Nagayasu, Takeru Nambu, Takayuki Nemoto, Ken‐ichi Hosoya · 2020 · Biological and Pharmaceutical Bulletin
  21. Impact of mAb-FcRn affinity on IgG transcytosis across human well-differentiated airway epithelium
    Kohei Togami, Whitney Wolf, Lucas C. Olson, Madison Card, Limei Shen, Alison Schaefer, Kenichi Okuda, Larry Zeitlin, Michael H. Pauly, Kevin J. Whaley et al. · 2024 · Frontiers in Immunology
  22. Rat as a Predictive Model for Human Clearance and Bioavailability of Monoclonal Antibodies
    Jason Robarge, Kevin M. Budge, Lucy Her, Andrea M. Patterson, Patricia Brown‐Augsburger · 2024 · Antibodies
  23. Prevention of Respiratory Syncytial Virus Infection: From Vaccine to Antibody
    Kelly Huang, Herren Wu · 2014 · Microbiology Spectrum
  24. Neutralization Activity of Anti-drug Antibodies Against a Biotherapeutic Can Be Predicted from a Comprehensive Pharmacokinetics, Pharmacodynamics, and Anti-drug Antibody Data Analysis
    Weifeng Xu, Brian M. Maas, Brad A. Roadcap, Aparna Swarup, Thomas Steinmetz, Linlin Luo, Marina Ichetovkin, Sandra Wood, Faye Vazvaei-Smith, Andrew Wen-Tseng Lee et al. · 2022 · The AAPS Journal
  25. The Development of Therapeutic Monoclonal Antibodies: Overview of the Nonclinical Safety Assessment
    Janice A. Lansita, Barbara Mounho-Zamora · 2015 · Current Pain and Headache Reports
  26. Two-Pore Minimum Physiologically-based Pharmacokinetic Model to Describe the Disposition of Therapeutic Monoclonal IgG Antibody in Humans
    Deni Hardiansyah, Chee M. Ng · 2018 · Pharmaceutical Research
  27. Design and characterization of protective pan-ebolavirus and pan-filovirus bispecific antibodies
    Ariel S. Wirchnianski, Elisabeth K. Nyakatura, Andrew S. Herbert, Ana I. Kuehne, Shawn A. Abbasi, Catalina Florez, Nadia Storm, Lindsay G. A. McKay, Leandrew Dailey, Erin A. Kuang et al. · 2024 · PLoS Pathogens
  28. Mechanistic models of humoral kinetics following COVID-19 vaccination
    Daniel Stocks, Amy C Thomas, Adam H.R. Finn, León Danon, Ellen Brooks‐Pollock · 2025 · Journal of The Royal Society Interface
  29. Antibody interfaces revealed through structural mining
    Yizhou Yin, Matthew G. Romei, Kannan Sankar, Lipika R. Pal, Kam Hon Hoi, Yanli Yang, Brandon C. Leonard, Gladys de Leon Boenig, Nikit Kumar, Marissa Matsumoto et al. · 2022 · Computational and Structural Biotechnology Journal
  30. Tixagevimab/cilgavimab for prevention and treatment of COVID-19: a review
    Andrew Ustianowski · 2022 · Expert Review of Anti-infective Therapy
  31. Antibody Prophylaxis Against Dengue Virus 2 Infection in Non-Human Primates
    Monika Simmons, Robert J. Putnak, Peifang Sun, Timothy H. Burgess, Wayne Anthony Marasco · 2016 · American Journal of Tropical Medicine and Hygiene
  32. Vaccinal antibodies: Fc antibody engineering to improve the antiviral antibody response and induce vaccine-like effects
    Dhuha H Nawab · 2021 · Human Vaccines & Immunotherapeutics
  33. A generic platform to couple affinity chromatography with native mass spectrometry for the analysis of therapeutic monoclonal antibodies
    Victoria C. Cotham, Anita P. Liu, Shunhai Wang, Ning Li · 2023 · Journal of Pharmaceutical and Biomedical Analysis
  34. Safety, Efficacy and Pharmacokinetics of AZD7442 (Tixagevimab/Cilgavimab) for Treatment of Mild-to-Moderate COVID-19: 15-Month Final Analysis of the TACKLE Trial
    Richard F. Hobbs, Hugh Montgomery, Francisco Padilla, Jesus Abraham Simón Campos, Douglas F. Arbetter, Seth Seegobin, Alexandre Kiazand, Katie L. Streicher, Nuria Martinez-Alier, Taylor S. Cohen et al. · 2024 · Infectious Diseases and Therapy
  35. Efficacy, Safety, and Pharmacokinetics of AZD7442 (Tixagevimab/Cilgavimab) for Prevention of Symptomatic COVID-19: 15-Month Final Analysis of the PROVENT and STORM CHASER Trials
    Myron J. Levin, Andrew Ustianowski, Stéphane De Wit, Rohini Beavon, Jesse Thissen, Seth Seegobin, Kanika Dey, Karen A. Near, Katie L. Streicher, Alexandre Kiazand et al. · 2024 · Infectious Diseases and Therapy
  36. [3D-CT investigation of craniofacial and cervical spine anomalies in congenital muscular torticollis].
    Tülay Özer, Lokman Uzun, Varîm Numanoğlu, Ahmet Savranlar, Mübin Hoşnuter, Sadi Gündoğdu · 2004 · PubMed
  37. An integrated methodology for quality assessment of therapeutic antibodies with potential long circulation half-life in harvested cell culture fluid using FcRn immobilized hydrophilic magnetic graphene
    Jianan Feng, Hao Cao, Yangjiayi Xiang, Chunhui Deng, Yan Li · 2024 · Talanta
  38. Current Strategies for Pharmacokinetic Optimization
    Uli Binder, Arne Skerra · 2015 · AAPS advances in the pharmaceutical sciences series
  39. Membrane Proteins as Targets for Biological Drugs
    Vanita D. Sood, Alec W. Gross · 2019 · Springer eBooks
  40. Harnessing mRNA-encoded PcrV-targeting monoclonal antibodies for combating antibiotic-resistant P. aeruginosa infections
    Xingyun Wang, Xingyue Gao, Cong Liu, Liang Yang, Liang Li, Nino Rcheulishvili, Ziqian Wang, Jiubiao Guo, Chuanlan Yang, Yueling Zheng et al. · 2025 · Molecular Therapy
  41. An antibody cocktail targeting conserved, nonoverlapping epitopes prevents viral escape and confers protection against RSV in vivo
    Yongpeng Sun, Liqin Liu, Zemin Jiang, Yizhen Wang, Jinghua Zhao, Hongsheng Qiang, Yujin Shi, Qi Lai, Li Chen, Qiangzhong Zhang et al. · 2026 · Science Translational Medicine
  42. Pharmacokinetics and Pharmacodynamics of Neonatal Fc Receptor (FcRn)-Targeting Therapeutic Proteins: a Systemic Review
    Girija Sharma, Yang Chen, Yan Chun Xu · 2023 · Current Pharmacology Reports
  43. Effect of FcRn Binding on Monoclonal Antibody Disposition in the Brain
    Hsien Wei Huang, Shengjia Wu, Shufang Liu, Dhaval K. Shah · 2025 · The AAPS Journal
  44. Respiratory Syncytial Virus Protein Structure, Function and Implications for Subunit Vaccine Development
    Michael McCarthy, Tonya L. Villafana, Elizabeth A. Stillman, Mark Thomas Esser · 2014 · Future Virology
  45. SKY59, A Novel Recycling Antibody for Complement-mediated Diseases
    Taku Fukuzawa, Jun‐ichi Nezu · 2019 · Current Medicinal Chemistry
  46. Implementation strategies for passive respiratory syncytial virus immunisation
    Charles Sande · 2021 · The Lancet Infectious Diseases
  47. Nirsevimab: hacia la inmunización universal de la población infantil frente al virus respiratorio sincitial
    Jordi Reina, Carla Iglesias · 2022 · Vacunas
  48. Reinventing Therapeutic Proteins: Mining a Treasure of New Therapies
    Sarfaraz K. Niazi, Zamara Mariam · 2023 · Biologics
  49. High Incidence of Respiratory Syncytial Virus in Children with Community-Acquired Pneumonia from a City in the Brazilian Pre-Amazon Region
    Valéria Costa Fontes, Hivylla Lorrana dos Santos Ferreira, Marilene Ribeiro, Aruanã Joaquim Matheus Costa Rodrigues Pinheiro, Carlos Eduardo Campos Maramaldo, Eduardo Willian de Alencar Pereira, Luís Batista, Antonio Júnior, Luís Felipe Lima Lobato, Fabiano Silva et al. · 2023 · Viruses
  50. Neonatal Genetic Delivery of Anti-Respiratory Syncytial Virus (RSV) Antibody by Non-Human Primate-Based Adenoviral Vector to Provide Protection against RSV
    Rika Gomi, Anurag Sharma, Wenzhu Wu, Stefan Worgall · 2018 · Vaccines
  51. Monoclonal Antibody Therapy Protects Pharmacologically Immunosuppressed Mice from Lethal Infection with Influenza B Virus
    Bindumadhav M. Marathe, Guha Asthagiri Arunkumar, Peter Vogel, Philippe Noriel Q. Pascua, Jeremy C. Jones, Richard J. Webby, Florian Krammer, Elena A. Govorkova · 2020 · Antimicrobial Agents and Chemotherapy
  52. Pharmacokinetic-Pharmacodynamic Modelling of Systemic IL13 Blockade by Monoclonal Antibody Therapy: A Free Assay Disguised as Total
    John Hood, Ignacio González-García, Nicholas White, Leeron Marshall, Vincent F. S. Dubois, Paolo Vicini, Paul Baverel · 2021 · Pharmaceutics
  53. Evaluation of strategies to modify Anti-SARS-CoV-2 monoclonal antibodies for optimal functionality as therapeutics
    Robert V. House, Thomas A. Broge, Todd J. Suscovich, Doris M. Snow, Milan T. Tomic, Genevieve H. Nonet, Kamaljit Bajwa, Guangyu Zhu, Zachary Martinez, Kyal Hackett et al. · 2022 · PLoS ONE
  54. Predicting pharmacokinetic profile of therapeutic antibodies after iv injection from only the data after sc injection in cynomolgus monkey
    Kenta Haraya, Tatsuhiko Tachibana, Jun‐ichi Nezu · 2016 · Xenobiotica
  55. Half-life extension and immunogenicity in therapeutic proteins: mechanisms, trade-offs, and a decision framework
    Yingping Chen, Yinchu Song, Yiwen Xie, Jianyi Pan · 2026 · Biochemical Pharmacology
  56. Systematic Review: Efficacy, Safety Profile, and Cost-Effectiveness of Nirsevimab Versus Palivizumab for RSV Prevention in Children Under 24 Months
    Andreea Văduva, Alexandru Dinulescu, Anca Cristina Drăgănescu, Sorin Claudiu Man, DA Plesca · 2026 · Children
  57. Development of therapeutic antibodies for the treatment of infection diseases and future aspect
    Kenta Haraya, Keisuke Gotanda, Rie Shiokawa, Maiko Hoshino, Chiyomi Kubo, Taichi Kuramochi · 2022 · Drug Delivery System
  58. Severe COVID-19: Drugs and Clinical Trials
    Hazael Ramiro Ceja-Gálvez, Francisco Israel Renteria-Flores, Ferdinando Nicoletti, Jorge Hernández‐Bello, Gabriela Macedo Ojeda, José Francisco Muñóz-Valle · 2023 · Journal of Clinical Medicine
  59. Monoclonal Antibodies: From Structure to Therapeutic Application
    Rong Deng, Junyi Li, C. Andrew Boswell, Amita Joshi, Chunze Li · 2024 · Springer eBooks
  60. Safety, pharmacokinetics and pharmacodynamics of SHR-1703, an innovative long-acting anti-interleukin-5 monoclonal antibody, in healthy subjects: a randomized, double-blind, dose-escalation, placebo-controlled phase I study
    Ling Yang, Yuan Fang, Yuan Luo, Meng Fu, Kai Shen, Zhu Luo · 2024 · Expert Opinion on Investigational Drugs
  61. Algorithmic multiscale analysis for the FcRn mediated regulation of antibody PK in human
    Dimitrios G. Patsatzis, Shengjia Wu, Dhaval K. Shah, Dimitris A. Goussis · 2022 · Scientific Reports
  62. Safety, tolerability, pharmacokinetics, and immunogenicity of an anti-SARS-CoV-2 monoclonal antibody HFB30132A after single dose intravenous administration in healthy Chinese subjects: a phase 1, randomized, double-blind, placebo-controlled study
    Shanshan Li, Xiaojie Wu, Nanyang Li, Guoying Cao, Jingjing Wang, Yuancheng Chen, Size Li, Jinjie He, Jufang Wu, Haijing Yang et al. · 2023 · Frontiers in Pharmacology
  63. Model-informed target product profiles of long acting-injectables for use as seasonal malaria prevention
    Lydia Burgert, Theresa Reiker, Monica Golumbeanu, Jörg J. Möhrle, Melissa A. Penny · 2021 · medRxiv
  64. Enhancement of Protein–Protein Interactions by Destabilizing Mutations Revealed by HDX-MS
    Yoshitomo Hamuro, Anthony Armstrong, Jeffrey D. Branson, Sheng‐Jiun Wu, Richard Y.‐C. Huang, Steven Jacobs · 2025 · Biomolecules
  65. Recent developments in pediatric respiratory syncytial virus prevention: The expanding role of monoclonal antibodies
    Christine E. Tabulov, Kristy M. Shaeer · 2026 · American Journal of Health-System Pharmacy
  66. Generation and characterization of QLS22001, a humanized monoclonal antibody that neutralizes IL-17A and IL-17F with an extended half-life
    Huimin Ma, Wei Zhang, Ke Liu, Baoxin Xu, Min-Yu Li, Qingyun Meng, Zhenming An, Bo Chen · 2023 · International Immunopharmacology
  67. Comparative Molecular Characterization and Pharmacokinetics of IgG1-Fc and Engineered Fc Human Antibody Variants to Insulin-like Growth Factor 2 Receptor (IGF2R)
    Chandra Bose Prabaharan, Sabeena Giri, Kevin J H Allen, Katrina E. M. Bato, Therese R. Mercado, Mackenzie E. Malo, Jorge Luis Costa CARVALHO, Ekaterina Dadachova, Maruti Uppalapati · 2023 · Molecules
  68. BMFPs, a versatile therapeutic tool for redirecting a preexisting Epstein-Barr virus antibody response toward defined target cells
    Benoît Gamain, Carine Brousse, Nathan Earl Rainey, Béré Diallo, Clara-Eva Paquereau, Alexandra Desrames, Jolita Ceputyte, Jean‐Philippe Semblat, Olivier Bertrand, Stéphane Gangnard et al. · 2022 · Science Advances
  69. Experience with Tixagevimab and Cilgavimab (Evusheld) in 86 rheumatic patients undergoing anti-B cell therapy with rituximab
    Tatiana Valentinovna Beketova, N. О. Levina, M. V. Dubinskaia, Yu. A. Uskova, I. V. Rozanova, V. V. Babak, M. F. Beketova, Tatyana N. Krasnova · 2023 · Rheumatology Science and Practice
  70. Bispecific antibodies: A promising entrant in cancer immunotherapy
    Samvedna Saini, Yatender Kumar · 2021 · Elsevier eBooks
  71. Mechanistically Weighted Metric to Predict In Vivo Antibody-Receptor Occupancy: An Analytical Approach
    Eshita Khera, Jaeyeon Kim, Andrew Marc Stein, Matt Ratanapanichkich, Greg M. Thurber · 2023 · Journal of Pharmacology and Experimental Therapeutics
  72. Long‐Circulating Nanobody Confers Durable Prophylaxis against Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Infection
    Geetha Satya Sainaga Jyothi Vaskuri, Gang Ye, Fan Bu, Dong Yang, Colleen Beth Jonsson, Hailey Turner‐Hubbard, Sydney R. Winecke, Alise Mendoza, Fang Li, Chalet Tan · 2025 · Advanced NanoBiomed Research
  73. Monoclonal antibodies in veterinary antiviral immunotherapy: technologies, applications and challenges
    Serkan Kökkaya, Ayşe Gençay Göksu, İbrahim Sözdutmaz, Muhammed Arif Toy, Engin Berber · 2025 · Veterinary Research Communications
  74. Multivalent nanobodies for potent and broad neutralization of Staphylococcus aureus toxins
    Y S Kim, Nicholas R. Walton, Wei Huang, Madison Lee, Yufei Xiang, Zhe Sang, Chaya Sussman, Sarah K. Moore, Derek J. Taylor, K Chen et al. · 2026 · Nature Communications
  75. Virus Reduction Neutralization Test and LI-COR Microneutralization Assay Bridging and WHO International Standard Calibration Studies for Respiratory Syncytial Virus
    Dengyun Sun, Ying Homan, Joseph M. Antonello, Danila G. Giacone, Leah Bogardus, Yuhua Zhang, Wen Ming Feng, Ivette Caro-Aguilar, Amy Han-Ming Hsu, Shara M. Dellatore et al. · 2022 · Bioanalysis
  76. Rapid depletion of “catch-and-release” anti-ASGR1 antibody in vivo
    Siva Charan Devanaboyina, Peng Li, Edward L. LaGory, Carrie Poon-Andersen, Kevin D. Cook, Marcus Soto, Zhe Wang, Khue Dang, Craig Uyeda, Ryan B. Case et al. · 2024 · mAbs
  77. Monoclonal Antibody Therapies Against SARS-CoV-2: Promises and Realities
    Daniele Focosi · 2024 · Current topics in microbiology and immunology
  78. “REAl LIfe” observational study on the effectiveness of Evusheld prophylaxis against SARS-CoV-2 omicron variants in vaccine non-responder immunocompromised patients (REALISE)
    Giuliana Lucia Esposito, Federico Fassio, Daniela Girardi, Erica Picasso, Federica Meloni, Simone Montini, Veronica Codullo, Eleonora Francesca Pattonieri, Irene Defrancesco, Antonio Bianchessi et al. · 2024 · Vaccine
  79. Engineered IgG Fc-conjugation prolongs the half-life of florfenicol and alleviates pneumonia in mice
    Shikun Ge, Mei Dang, Alberto Carlos Pires Dias, Xiaoying Zhang · 2024 · Biochimie
  80. A humanised ACE2, TMPRSS2, and FCGRT mouse model reveals the protective efficacy of anti-receptor binding domain antibodies elicited by SARS-CoV-2 hybrid immunity
    Fernanda Ana‐Sosa‐Batiz, Shailendra Kumar Verma, Norazizah Shafee, Robyn Miller, Chris Conner, Kathryn M. Hastie, Julia Timis, Erin Maule, Michael N. Nguyen, Linda Tran et al. · 2025 · EBioMedicine
  81. An antidote approach to reduce risk and broaden utility of antibody-based therapeutics
    Alyse D. Portnoff, Cuihua Gao, M. Jack Borrok, Xizhe Gao, Changshou Gao, G. Jonah Rainey · 2017 · Journal of Biological Chemistry
  82. Physiology and Pathology of Multidrug-Resistant Bacteria: Antibodies- and Vaccines-Based Pathogen-Specific Targeting
    Yang Zhang, Jie Su, Donghui Wu · 2017 · InTech eBooks
  83. RECOMBINANT ANTIBODIES IN ANTI-VIRAL THERAPY: ACHIEVEMENTS AND PERSPECTIVES
    Alexey S. Oksanich, Alexandra A. Nikonova, Vitaly V. Zverev · 2018 · Journal of microbiology epidemiology immunobiology
  84. Pharmacological and non-pharmacological strategies in coronavirus disease 2019: A literature review
    Francisco J. González-Ruiz · 2022 · Annals of Medicine and Surgery
  85. Respiratory Syncytial Virus Vaccines and Monoclonal Antibodies
    Ruth A. Karron · 2023 · Elsevier eBooks
  86. [Progress in monoclonal antibody-based immunotherapy for cancer treatment].
    Yajun Guo · 2015 · PubMed
  87. Role of IgD in prevention and treatment of SARS CoV-2 infection “The Hidden Soldier"
    Donia H. Sheir · 2020 · Microbial Biosystems
  88. Improvement of Key Characteristics of Antibodies
    Neil Brewis · 2020 · Learning materials in biosciences
  89. A highly expressing, soluble, and stable plant-made IgG fusion vaccine strategy enhances antigen immunogenicity in mice without adjuvant
    Andrew G. Diamos, Mary D. Pardhe, Haiyan Sun, Joseph G. L. Hunter, Jacquelyn A. Kilbourne, Qiang Chen, Hugh S. Mason · 2020 · bioRxiv (Cold Spring Harbor Laboratory)
  90. Safety, Tolerability and Plasmodium Falciparum Transmission-Reducing Activity of Monoclonal Antibody TB31F: An Open-Label, First-in-Human, Trial in Healthy Malaria-Naïve Adults
    Saskia C. van der Boor, Merel J. Smit, Stijn W. van Beek, Jordache Ramjith, Karina Teelen, Marga van de Vegte‐Bolmer, Geert‐Jan van Gemert, Peter Pickkers, Yimin Wu, Emily Locke et al. · 2022 · SSRN Electronic Journal
  91. Antibody-Based Therapeutics for Hypercholesterolemia
    Brian Tomlinson, Paul Chan · 2025 · Biologics
  92. Pharmacokinetic considerations and strategies for antibody-based therapeutics
    Juanhong Zhang, Rong Chang, Anpeng Zhao, Xuefeng Li, Yuemei Sun, Junmin Zhang, Rong Wang, Tengchuan Jin · 2025 · Drug Metabolism Reviews
  93. Efficacy and safety of Monoclonal Antibodies in Malaria Protection and Prevention of Transmission: A Systematic Review
    Kanika Verma, Richa Singhal, Anup R. Anvikar, Praveen Kumar Bharti, Nitika Nitika · 2025 · Clinical Therapeutics
  94. Quantitative Prediction of Human Pharmacokinetics for Fc‐Engineered Therapeutic Monoclonal Antibodies With Increased FcRn Binding Mutations After Subcutaneous Injection
    Kenta Haraya, Taichi Kuramochi · 2026 · Clinical and Translational Science
  95. Open-label phase 1b/2 trial of navenibart, a long-acting plasma kallikrein inhibitor for hereditary angioedema
    Aleena Banerji, Timothy Craig, Karl V. Sitz, H. Henry Li, William Lumry, Adil Adatia, William Yang, Josh S. Jacobs, Raffi Tachdjian, Weily Soong et al. · 2026 · Journal of Allergy and Clinical Immunology
  96. YTE-engineered antibodies: From neonatal Fc receptor binding mechanisms to next-generation therapeutics
    Suneetkumar Diwakar Dubey · 2026 · International Journal of Molecular and Immuno Oncology
  97. Broadly neutralizing nanobodies target a defined structural pivot site on the RSV fusion protein
    Qianqian Wang, Xianliang Ke, Entao Li, Dongxiang Hong, Zekai Cheng, Hongxin Li, Jiachen Zhang, Tengchuan Jin, Rui Gong, Bo Shu et al. · 2026 · EMBO Molecular Medicine
  98. High-dose biologics and bioconjugates delivery: Integrating molecular optimization with device design and routes of administration
    Naresh K. Budhavaram, Kevin Harrison Duffy, Abraham H. Abouzeid, Reshma Bharadwaj, Nisha Shrestha, Elisa Schrader Echeverri, Chris Mitchener, J. Anand Subramony · 2026 · Advanced Drug Delivery Reviews
  99. The preclinical discovery and development of depemokimab for severe eosinophilic asthma
    Mario Cazzola, Vincenzo Patella, Raffaella Pagliaro, Andrea Bianco, Paola Rogliani, Maria Gabriella Matera · 2026 · Pulmonary Pharmacology & Therapeutics
  100. Advances in respiratory syncytial virus therapeutics: A comprehensive review of small-molecule inhibitors, monoclonal antibodies, and vaccines
    Guangqiang Bai, XJ Huang, Yong He · 2026 · European Journal of Medicinal Chemistry